≡Menu

Category Archives: Class Action

April 01

Class Action, ERISA

Coca-Cola Bottling Company Can’t Shake Lawsuit Over Mismanaged Retirement Plans

On March 31, 2021, a district judge for the United States District Court for the Western District of North Carolina determined that a class action lawsuit against Coca-Cola Consolidated, Inc., and its Corporate Benefits Committee (collectively, “Coke Bottling,” the “Company,” or “Defendants”), was fit to proceed, denying the Company’s attempt to dismiss the legal action. The lawsuit stems from allegations that the Company mismanaged its defined contribution retirement plan (the…

March 26

Class Action

Honda Can’t Dismiss ‘Sudden Deceleration’ Lawsuit

On March 25, 2021, the United States District Court for the Central District of California determined that a class action lawsuit against American Honda Motors, Inc. (“Honda” or the "Company") was fit to proceed, denying Honda’s attempt to dismiss the legal action. Plaintiffs, represented by Miller Shah LLP, allege that certain of Honda’s model Acura MDX from years 2016 to 2020 and model Acura RDX from years 2019 to 2020…

March 24

Class Action, Products Liability

American Honda: Court Grants Class Certification in ‘HFL Defect’ Lawsuit

On March 23, 2021, a District Judge in the United States District Court for the Northern District of California granted Plaintiffs’ Motion for Class Certification in an action against American Honda Motors, Inc. (“Honda”), denying Honda’s Motion to Strike Expert Testimony in the process. In 2016, Plaintiffs filed a lawsuit alleging that Honda failed to disclose a defect in the “hands free” calling system, HandsFreeLink™ (“HFL”), featured in the 2004…

July 01

Class Action, False Claims Act, FCA Qui Tam, Whistleblowers

Novartis Pays Over $642 Million to Settle FCA Allegations

On July 1, 2020, the Department of Justice (“DOJ”) announced that Novartis Pharmaceutical Corporation (“Novartis”), a New Jersey-based pharmaceutical company, agreed to pay over $642 million in separate to resolve alleged violation of the False Claims Act (“FCA”), 31 U.S.C. §§ 3729–3733. The settlement resolves allegations that Novartis made improperly payments to Medicare patients and prescribing physicians to promote Novartis's drugs, Gilenya and Afinitor. The FCA allows private citizens (known…

January 06

Class Action, False Claims Act, FCA Qui Tam, Whistleblowers

Teva Agrees to $54 Million Settlement to Resolve FCA Whistleblower Suit

On January 6, 2020, Teva Pharmaceuticals agreed to a $54 million settlement to resolve a False Claims Act action brought against Teva Pharmaceuticals USA, Inc., Teva Neuroscience, Inc., and Teva Sales and Marketing, Inc. (collectively “Teva”). The settlement resolves allegations that Teva violated the False Claims Act and the Anti-Kickback Statute by using speaker events to bribe doctors to prescribe two of its drugs, Copaxone and Azilect. The False Claims…

While this website provides general information, it does not constitute legal advice. The best way to get guidance on your specific legal issue is to contact a lawyer. To schedule a meeting with an attorney, please call 866-540-5505 or complete the intake form to email us. To inquire about employment opportunities with Miller Shah LLP, please see our Opportunities page.

Offices Throughout
the United States & Italy

Get Fort Lauderdale Directions

IT Milan

Fax number

866-540-5505

Telephone

Attorney Advertising. This information is designed for general information only. The information presented should not be construed to be formal legal advice nor the formation of a lawyer/client relationship. Past results and testimonials are not a guarantee, warranty, or prediction of the outcome of your case, and should not be construed as such. Past results cannot guarantee future performance. Any result in a single case is not meant to create an expectation of similar results in future matters because each case involves many different factors, therefore, results will differ on a case-by-case basis. By providing contact information, users acknowledge and give explicit consent to be contacted via the methods of communication provided, including SMS. Message and data rates may apply. Message frequency may vary. Reply STOP to opt out.